Science World Publishing

Open Access Journal | Volume: 1.1

CURRENT TRENDS IN MEDICAL AND CLINICAL CASE REPORTS

Crossref

Tumor Cell Antigenicity as Performance Hierarchy of Equilibrating Interactivity of Systems of Receptivity and Activation of Lymphocyte Subsets

Lawrence M. Agius

Department Of Pathology, University Of Malta Medical School, Mater Dei Hospital, Tal-Qroqq, Msida, 27 "Ballarat", Guzeppe Caruana Street, Tal-Virtu, Rabat, Rbt09, Malta, Europe

Article Information

Article Type: Case Studies
Journal Type: Open Access
Volume: 1 **Issue:** 1
Manuscript ID: CTMCCR-1-105
Publisher: Science World Publishing

Received Date: 01 September 2020
Accepted Date: 10 September 2020
Published Date: 12 September 2020

***Corresponding author:**

Lawrence M. Agius

Department Of Pathology
University Of Malta Medical School
Mater Dei Hospital, Tal-Qroqq
Msida, 27 "Ballarat"
Guzeppe Caruana Street, Tal-Virtu
Rabat, Rbt09, Malta
Europe
Email: lawrence.agius@um.edu.mt

Citation: Lawrence M. Agius (2020) Tumor Cell Antigenicity as Performance Hierarchy of Equilibrating Interactivity of Systems of Receptivity and Activation of Lymphocyte Subsets. Current Trends Med Clin Case Rep, 1(1);1-3

ABSTRACT

A multifold dimensionality within equilibrating performance of the immune response belies the development of hierarchical dimensions as conveyed by development of evolutionary dynamics of such immune response. The realization of significance in activation of both helper and cytotoxic T lymphocytes reflects the complexity of immunogenicity as a web-wide dimension in the further projection of injury to systems of tumor proliferation and infiltration of brain tissue. It is perhaps within systems of enhanced participation of tumor cell release of antigens that there exists the equilibration performance for further modification of the immune response towards tumor dynamics and cell constitutive series of antigen identities.

INTRODUCTION

The scope of introduction and maturation of dendritic cells constitutes the harnessing of a multi-potent derivative of circulating and bone marrow progenitors as termed professional antigen-presenting cells. Studies suggest improved overall survival and of progression free survival with dendritic cell therapy [1]. Immunotherapy shows great promise in patients with high-grade glioma [2,3]. In the realization of injury to tumor cells in general and of intracranial brain tumors in particular, it is significant to consider dendritic cells within a body-wide web of receptor and effector cells borne out by systems of recognition of antigen presentation [4]. In such terms the incremental derivation of antigen presence is inherently linked to activation of the naïve lymphocytes as significantly projected by lymphoid tissue and thymus. Recent trials have shown that dendritic cells promote an anti-tumor immune response and sensitize glioma cells to chemotherapy [5]. The development of derivation dynamics is further enhanced as portrayed by dynamics of expansion of the dendritic cells that can be accomplished ex vivo.

ANTIGEN DERIVATION

Pronounced derivation of antigen processing and presentation is central to a whole series of tumor cell extract recognition as evidenced by systems for further activation and proliferation of both CD4+ T cells and of cytotoxic CD8+ cells. It may be necessary to evaluate molecular genetic abnormalities in individual patient tumors formulate novel immunotherapeutic strategies [6]. In such terms, the performance attributes of antigen presentation provoke the evolutionary development of immune activation within systems of proliferation and spread of brain tumor cells. Peptide-based immunotherapy could be a new treatment modality in patients with glioma [7]. It is further to such considerations that the escape phenomenon of antigens that are not recognized by the immune systems evolves in terms of acquisition and repeated degradation of major histocompatibility complex molecules as portrayed within systems of enhanced recognition/sensitization of immune effector cells. Dendritic cells are potent initiators of adaptive immune responses and hence central players in immunotherapy [8].

WEAK ANTIGENICITY

The problematic weakness of antigenicity of tumor suppressor cells is paramount consideration of the realization of tumor antigen presentation to immune effector cells. Considering the heterogeneity of malignant gliomas and an immune-refractory tumor cell population, rational multiple modalities that target different characteristics of the neoplasm may prove the most effective therapeutic strategy [9]. In such terms, the overall dynamics of equilibrating processes of exchange and of cross presentation constitute evidential support to the endogenous versus exogenous presentation processes as directed to CD4+ T lymphocytes in particular. Insight into the complex dynamics of immune-

tumor interactions promises to delineate mechanisms of immune synergy with other treatment modalities [10]. An equilibrating scenario of induced lymphocyte effector activation is predominant in the realization of a whole series of processing events that include in particular a series of co-stimulatory molecules on the tumor cell surface.

Composite dimensions as evidential processing of antigens is especially effective with regard to dendritic cells as further pronounced within systems of performance of activation phenomena specifically involving T lymphocytes. A number of immunobiologic features of the brain and of gliomas may critically affect the regulation of effective treatment, including the presence of the blood brain barrier and the lack of organised secondary lymphatic tissues, low expression of histocompatibility antigens and the presence of immunosuppressants produced by the glioma cells [11]. In terms of involvement of injury, the realization of bacteria and other extrinsic sources of foreign antigens constitutes a strict characterization of the dynamics of expression of tumor associated antigens per se. It is further to the embodied dimensions of lymphocyte activation that these constitute the development of effector roles for the immune system as integral whole series of web-based interactivities. Cross-talk occurs between T cells and hematopoietic stem cells during adoptive cellular therapy for high grade gliomas [12].

EQUILIBRATING PERFORMANCE

The equilibrating performance derivatives of antigen presentation by dendritic cells constitute the hierarchical system profile of the immune system as integral presentation dependence as borne out by the consequent evolutionary traits of effector immune system participation. Evidence supports a significant interplay between gliomagenesis and the immune system; CD8+ T-cell infiltrates are related to prolonged survival [13]. In such terms, constitutive response of the immunogenicity of tumor cells is a conditioned reappraisal phenomenon that performs multi functional activation within body wide web participation. The significance roles for a complex of pathogenetic pathways are well illustrated by the evolutionary role of antigen presentation that is primarily activating. It is performance dynamics of immunogenicity as a single step in antigen-presentation phenomena that constitute the realization of pathways of adverse dimensions; this is illustrated by the possible emergence of autoimmune demyelination as a toxic byproduct in the constitution of the immunogenicity as offered by tumor cell beds and in particular by infiltrating tumor cells.

SYSTEMS OF ACTIVATION

Equilibrating and recognition indices of activation of the immune system are a performance dynamics that incorporates dendritic cells as a specific web-based activity. Adjuvant immunotherapy utilising whole-cell sate dendritic cell vaccine may extent short-term survival [14]. It is paramount to consider weak antigenicity of tumor cells in terms of constitutional equilibration as presented by cell surface receptivity in the first instance. In such terms, ongoing derivation of lymphocyte activation perform a realization of stimulated and co-stimulated forces as portrayed by a whole series of cytokine production and secretion of effector lymphocytes.

CONCLUDING REMARKS

The derivational dynamics of lymphocyte activation are performance attributes of antigen presentation by dendritic cells in particular and as evidenced by systems of provoking profile within body-wide web activity.

The field of immunotherapy is advancing in terms of the active specific immunotherapy utilising autologous dendritic cells as vehicle for immunisation [15].

The antigenicity derivative formulas are depicted by the emergence of constitutional immunity that first recognizes foreign antigens and then processes such antigens in terms of tumor cell immunogenicity. It is further to considerations of such performance that the immune system is primarily antigen-presenting within a strict hierarchy of constitutional equilibration of endogenous and exogenous derived presentation of such antigens. Dendritic cells are essential for priming but ineffective for boosting antitumor immune response in a murine model of glioma [16].

Significant property for change in activation status is further projected as immune derivation of partly processed or fragmented antigens within systems receptive for further stimulation of anti-glioma injury as constituted by infiltrating tumor cells within the central nervous system. The realization of injury is significant within such hierarchical systems of interactivity as evidenced by performance dynamics of the immune response.

BIBLIOGRAPHY

1. Vatu BI, Artene S-A, Staicu A-G, Turcu-Stiolica A, Folcuti C, Dragoi A, et al. Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review" J Immunoassay Immunochem. 2019;40(1):70-80.
2. Artene SA, Turcu-Stiolica A, Ciurea ME, Folcuti C, Tataranu LG, Alexandru O, et al. Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials. Sci Rep. 2018;8(1):11800.
3. Cao J-X, Zhang X-Y, Liu J-L, Li D, Li J-L, Liu Y-S, et al. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma: evidence from a meta-analysis. PLoS One. 2014;9(9):e107173.
4. Wang X, Zhao H-Y, Zhang F-C, Sun Y, Xiong Z-Y, Jiang X-B. Dendrtic cell-based vaccine for the treatment of malignant glioma: a systematic review. Cancer Invest. 2014;32(9):451-7.
5. Luptrawan A, Liu G, Yu JS. Dentritic cell immunotherapy for malignant gliomas. Rev Recent Clin Trials. 2008 Jan;3(1):10-21.
6. Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009;32(3):265-73.
7. Yamanaka R, Itoh K. Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opin Biol Ter. 2007;7(5):645-9.
8. Fo;;eu A. Dey M. Dendritic cell based vaccination strategy: an evolving paradigm. J Neurooncol. 2017;133(2):223-235.
9. Akasaki Y, Black KL, Yu JS. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches" Front Biosci. 2005;10:2908-21.
10. Wheeler CJ, Black KL. Dendritic cell vaccines and immunity in glioma patients. Front Biosci. 2005;10:2861-81.
11. Pollack IF, Okada H, Chambers WH. Exploitation of immune mechanisms in the treatment of central nervous system cancer. Semin Podiatry Neural. 2000;7(2):131-43.
12. Wildes TJ, Grippin A, Dyson KA, Wummer BM, Damiani DJ, Abraham RS, et al. Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma. Clin Cancer Res. 2018;24(16):3955-3966.
13. Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, et al. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 2010;17(11):1381-5.
14. Cho D-Y, Yang W-K, Lee H-C, Hsu D-M, Lin H-L, Lin S-Z, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiform: a phase II clinical trial. World

Neurosurg. 2012;77(5-6):736-44.

15. Van Good S, Maes W, Ardon H, Verschuere T, V Cauter S, de Vkeeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 2009;19(4):694-712.

16. Jouanneau E, Poujol D, Le Mercier I, Blay JY, Belin MF, Puisieux I. Dendritic cells are essential for priming but inefficient for boosting antitumor immune response in an orthotropic murine glioma model. Cancer Immunol immunother. 2006;55(3):254-67.